NasdaqGS:RPRXPharmaceuticals
Royalty Pharma (RPRX): Reassessing Valuation After MYQORZO’s FDA Approval Unlocks New Royalty Cash Flows
The FDA approval of MYQORZO for obstructive hypertrophic cardiomyopathy has initiated Royalty Pharma (RPRX)'s royalty stream and repayment terms, a material catalyst that strengthens its long-term cash flow profile.
See our latest analysis for Royalty Pharma.
This latest FDA milestone lands on top of a strong run, with the share price up 50.68 percent year to date and a 12 month total shareholder return of 57.78 percent. This suggests momentum is building as investors reassess Royalty...